NEW YORK, January 1, 2026, 15:38 ET — Market closed
- AbbVie shares last closed down 0.5% at $228.49 on Wednesday.
- Wall Street ended 2025’s final session lower in thin holiday trading.
- Attention turns to the Fed’s late-January meeting and AbbVie’s mid-January dividend record date.
AbbVie Inc. shares last closed down 0.5% at $228.49 on Wednesday, the final U.S. trading session of 2025, with Wall Street closed on Thursday for the New Year’s Day holiday.
The market closure matters because AbbVie and other large-cap drugmakers often act as a defensive trade when investors reassess risk at the start of a new year. With liquidity returning in the next session, traders will be watching whether late-December selling pressure persists.
U.S. stocks ended lower on Wednesday, with the S&P 500 down 0.74%, the Nasdaq off 0.76% and the Dow down 0.63%, Reuters reported.
“It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking in low-liquidity conditions. Reuters
AbbVie traded between $228.43 and $230.25 in Wednesday’s session after opening at $229.74, according to the company’s investor relations stock-quote page.
The stock sits about 6.7% below its 52-week high of $244.81 and roughly 39% above its 52-week low of $164.39, levels technicians often use as near-term resistance and support markers.
Chart watchers also note AbbVie is above its 50-day moving average of about $226.70 and its 200-day moving average near $205.99, according to Yahoo Finance statistics.
The drugmaker has been working to offset the decline of former blockbuster Humira after it began facing U.S. biosimilar competition, leaning on newer immunology medicines such as Skyrizi and Rinvoq.
Income-focused investors have another near-term catalyst: AbbVie’s board last announced a quarterly dividend of $1.74 per share payable Feb. 17, 2026, to shareholders of record on Jan. 16, 2026.
Peer moves were mixed in the last session. Johnson & Johnson was little changed, while Merck and Pfizer fell and Eli Lilly dipped, as the healthcare sector also softened.
Before the next session, investors will gauge whether the market’s year-end slide extends into early 2026 after Wall Street finished the final trading day lower in holiday-thinned conditions.
Macro focus is also building ahead of the Federal Reserve’s Jan. 27–28 policy meeting; investors currently expect the central bank to leave rates unchanged, Reuters reported earlier this week.
For AbbVie specifically, traders will watch whether shares hold above the mid-$220s area around the 50-day average and stay within striking distance of the $244.81 52-week high, while awaiting the company’s next earnings update and any guidance on the post-Humira transition.
Related articles: NYSE:ABBV
